Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erythropoietic Response in HCV Patients Receiving RBV/IFN or RBV/PEG-IFN
NCT00328549Phase 2Completed
- Sponsor
- Ortho Biotech Inc.
- Start
- Oct 2001
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands, Metabolically Activated Prodrugs
01
Overview
A Phase 2 trial of pegylated interferon alpha, ribavirin in hepatitis C (HCV), sponsored by Ortho Biotech Inc.. Started Oct 2001; status: completed.
02
Drugs
pegylated interferon alpharibavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00328549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00328549.